STARSHIP 2006.

Methods	6‐Week wash‐out period 6‐Week multi‐centre open‐label randomised trial
Participants	696 Hispanic men and women from the USA with hypercholesterolaemia aged > 17 years; LDL‐C 130 to 300 mg/dL (3.36‐7.76 mmol/L), TG < 400 mg/dL (4.51 mmol/L) 339 participants received atorvastatin, 357 received rosuvastatin Exclusion criteria: homozygous familial type I, III or V hypercholesterolaemia; active arterial disease, uncontrolled HTN, poorly controlled diabetes mellitus, active liver disease of hepatic dysfunction, unexplained CK increase > 3 × ULN Atorvastatin 10 mg/d baseline TC: 6.41 mmol/L (247 mg/dL) Atorvastatin 10 mg/d baseline LDL‐C: 4.24 mmol/L (164mg/dL) Atorvastatin 10 mg/d baseline HDL‐C: 1.24 mmol/L (48 mg/dL) Atorvastatin 10 mg/d baseline TG: 2.02 mmol/L (179 mg/dL) Atorvastatin 20 mg/d baseline TC: 6.44 mmol/L (249 mg/dL) Atorvastatin 20 mg/d baseline LDL‐C: 4.27 mmol/L (165 mg/dL) Atorvastatin 20 mg/d baseline HDL‐C: 1.21 mmol/L (47 mg/dL) Atorvastatin 20 mg/d baseline TG: 2.10 mmol/L (186 mg/dL)
Interventions	Atorvastatin 10 mg/d Atorvastatin 20 mg/d Rosuvastatin 10 mg/d Rosuvastatin 20 mg/d
Outcomes	Per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	Atorvastatin groups were analysed                 SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d and atorvastatin 20 mg/d; interventions were analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d and atorvastatin 20 mg/d; interventions were analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d and atorvastatin 20 mg/d; interventions were analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Atorvastatin 10 mg/d: 7/168 were not included in the efficacy analysis because of withdrawal of consent, adverse events, loss to follow‐up Atorvastatin 20 mg/d: 10/171 were not included in the efficacy analysis because of withdrawal of consent, adverse events, loss to follow‐up 5% of participants were excluded from the efficacy analysis
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	High risk	AstraZeneca funded the study; data may support bias against atorvastatin.